Introduction
============

Gastric cardia adenocarcinoma (GCA) is characterized by short disease duration and poor prognosis ([@b1-ol-0-0-11173]). GCA has a high incidence rate (\~3.3 new cases per 100,000 per year) worldwide ([@b2-ol-0-0-11173]), and is much higher in China, with 49.59 new cases per 100,000 per year ([@b3-ol-0-0-11173]). GCA presents with non-specific symptoms at the early stages of the disease, and the majority of patients are diagnosed at an advanced stage; consequently, patients with GCA have a low survival rate ([@b4-ol-0-0-11173],[@b5-ol-0-0-11173]). Previous studies have revealed that early diagnosis and treatment of GCA improves patient outcomes and results in a more favorable prognosis ([@b6-ol-0-0-11173],[@b7-ol-0-0-11173]). The currently available methods for the early diagnosis of GCA include barium X-ray radiography ([@b8-ol-0-0-11173],[@b9-ol-0-0-11173]), endoscopy ([@b10-ol-0-0-11173],[@b11-ol-0-0-11173]), abdominal ultrasound ([@b12-ol-0-0-11173]), spiral computed tomography ([@b13-ol-0-0-11173],[@b14-ol-0-0-11173]) and proton nuclear magnetic resonance ([@b15-ol-0-0-11173],[@b16-ol-0-0-11173]). However, these methods are invasive and not cost-effective ([@b17-ol-0-0-11173]). Therefore, there is a requirement for a non-invasive, cost-effective and efficient method to diagnose early GCA and improve patient prognosis.

Systems biology and high-throughput screening methods have revealed that the incidence of GCA is associated with mutations in tumor protein P53 ([@b18-ol-0-0-11173],[@b19-ol-0-0-11173]) and the vitamin D receptor ([@b20-ol-0-0-11173]), as well as polymorphisms in the Fas ligand gene ([@b21-ol-0-0-11173]) and thymidylate synthase ([@b22-ol-0-0-11173]). In addition, proteins such as cancer antigen 125 and minichromosome maintenance 5 serve as potential biomarkers for the early diagnosis of GCA ([@b23-ol-0-0-11173],[@b24-ol-0-0-11173]). However, the aforementioned genes and proteins lack specificity and sensitivity, and previous studies have revealed that a single biomarker is unlikely to accurately diagnose GCA ([@b23-ol-0-0-11173],[@b25-ol-0-0-11173]). Laser capture microdissection-based proteome analysis on human GCA tissues revealed that 23 proteins are abnormally expressed in patients with GCA compared with healthy controls ([@b26-ol-0-0-11173]). Metabolomics has been widely applied for the diagnosis for several types of cancer, including colorectal ([@b27-ol-0-0-11173],[@b28-ol-0-0-11173]), liver ([@b29-ol-0-0-11173]), pancreatic ([@b30-ol-0-0-11173],[@b31-ol-0-0-11173]) and gastric ([@b32-ol-0-0-11173],[@b33-ol-0-0-11173]) cancer. However, a limited number of studies have investigated a metabolomics-based approach for the diagnosis of GCA ([@b34-ol-0-0-11173],[@b35-ol-0-0-11173]). Cai *et al* ([@b34-ol-0-0-11173]) have suggested that the metabolites and proteins associated with glycolysis may serve as potential biomarkers for the diagnosis of GCA; however, an established diagnostic model has not been reported.

The present study aims to identify potential biomarkers for the early detection of GCA. The ultra-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry (UPLC/Q-TOF MS) was utilized to establish the metabolic fingerprints of patients with GCA and healthy controls, and the specific biomarkers associated with GCA were screened to develop an early diagnostic model. Furthermore, metabolic pathway analysis was performed to investigate the pathways associated with the pathogenesis of GCA.

Materials and methods
=====================

### Chemicals

Isopropanol \[high-performance liquid chromatography (HPLC)-grade\], acetonitrile (HPLC-grade), methanol (HPLC-grade) and formic acid (98%) were purchased from J.T. Baker; Avantor, Inc. The internal standard L-2 chlorophenylalanine was obtained from Ark Pharm, Inc. and ultrapure water was purchased from EMD Millipore.

### Clinical samples

The present study was approved by the Ethics Committee of the People\'s Hospital of Yangzhong City (Yangzhong, China) and all participants provided written informed consent. Plasma samples were obtained from 21 patients with GCA (14 males and 7 females; mean age, 66 years; age range, 60--80 years) and 48 healthy volunteers (14 males and 34 females; mean age, 52.15 years; age range, 40--68 years) at the People\'s Hospital of Yangzhong City between July and December 2015. Patients with GCA were diagnosed by gastroscopy and had not received chemotherapy or other therapy, including surgery and radiotherapy. A mucosal biopsy was performed to classify patients according to the Tumor-Node-Metastasis (TNM) Classification of Malignant Tumors ([@b36-ol-0-0-11173]). The clinical information of the participants is summarized in [Table I](#tI-ol-0-0-11173){ref-type="table"}.

A total of 5 ml peripheral venous blood was obtained from the participants and collected in anticoagulation tubes containing heparin sodium. The blood was centrifuged at 670 × g for 15 min at 4°C, and the supernatant was collected and stored at −80°C until further analysis.

### Sample preparation

Plasma samples were thawed on ice prior to analysis. A total of 100 µl plasma was added to 300 µl methanol and acetonitrile mixture (1:1) containing 5 µg/ml L-2 chlorophenylalanine internal standard, which was used to check the integrity of the automated integration and to assess instrument performance throughout the batch analysis. The mixture was vortexed for 30 sec and maintained at 4°C for 1 h, vortexed again for 30 sec and maintained at 4°C for 3 h. The mixture was vortexed and centrifuged at 37,730 × g for 10 min at 4°C. Subsequently, 300 µl of the supernatant was centrifuged at 37,730 × g for 10 min at 4°C, and 200 µl supernatant was decanted into a vial with an inner cannula.

To monitor the robustness of sample preparation and the stability of instrument analysis, a quality control (QC) sample was prepared by pooling 10 µl plasma from all samples.

### UPLC-Q/TOF MS analysis

The UPLC analysis was performed in a Waters Acquity™ Ultra-performance LC system coupled with a Waters Micromass™ Q/TOF MS (Waters Corporation). The chromatographic separation was performed on an ACQUITY BEH-C18 column (2.1×100 mm; 1.7 µm; Waters Corporation). The mobile phase is composed of (A) 0.1% formic acid and (B) isopropanol, acetonitrile and methanol \[20:40:40 (v/v)\] in 0.1% formic acid, and the gradient was used as follows: 98--50% (A) and 2--50% (B) for 0--3.5 min; 50--0% (A) and 50--100% (B) for 3.5--20 min. The flow rate was 0.4 ml/min. The temperature of the autosampler and the chromatographic column was maintained at 4 and 50°C, respectively. A total of 5 µl sample solution was injected per run. The MS scan ranged from 50--1,000 m/z in the positive and negative ion mode. The cone and capillary voltages were set at 35 V and 3.0 kV for positive ionization mode, and 35 V and 2.8 kV for negative ionization mode. The collision energy was set at 4 eV. A desolvation gas flow rate of 600 l/h at 115°C was used. The data acquisition rate was set to 0.3 spec/sec. Data acquisition was performed using Waters MassLynx software (version 4.1; Waters Corporation).

### Data processing

Prior to statistical analysis, raw data were imported into the Progenesis QI software package (version 2.0; Waters Corporation) for data standardization. The orthogonal partial least squares discriminant analysis (OPLS-DA) model was performed using SIMCA software (version 14.1; Umetrics Ltd.). Potential biomarkers were identified from loading plots constructed following analysis with OPLS-DA, and the biomarkers were selected based on the variable importance in the projection (VIP) value. The model parameters of R2Y(cum) is used to estimate the 'goodness of fit' of the model, and Q2 (cum) estimates the ability of prediction. The S-plot is used to visualize both the covariance and the correlation structure between the X-variables and the predictive score t\[1\]. Thus, the S-plot is a scatter plot of the p\[1\] vs. p(corr)\[1\] vectors of the predictive component. A response permutation test with 200 iterations was performed to assess the risk that the current OPLS-DA model is spurious. The structure of the differential metabolites was identified using the Human Metabolome Database (HMDB; version 4.0; [www.hmdb.ca/spectra/ms/search](www.hmdb.ca/spectra/ms/search)) and The LIPID MAPS Lipidomics Gateway (updated March 9th, 2016; [www.lipidmaps.org](www.lipidmaps.org)) based on secondary mass spectrometry information.

### Statistical analysis

Statistical analyses were performed using SPSS software (version 19.0; IBM Crop.). Student\'s t-test was performed to compare the differences in metabolite levels between healthy subjects and patients with GCA. P\<0.05 was considered to indicate a statistically significant difference. The diagnostic abilities of the biomarkers were assessed by systematic cluster analysis, receiver operating characteristic (ROC) curves and binary logistic regression. In addition, the pathway analysis module of MetaboAnalyst software (version 4.0; [www.metaboanalyst.ca](www.metaboanalyst.ca)) ([@b37-ol-0-0-11173]) was used to analyze significant metabolic pathways, which has pathway impact value of no less than 0.1 and -log(p) value of no less than 2.

Results
=======

### UPLC-Q/TOF MS analysis of plasma samples

A total of 69 samples were analyzed in a random order, and QCs were inserted into the analysis sequence to monitor and correct changes in the instrument response. To identify and remove probable characteristic peaks caused by source contaminants, test tube components or solvent impurities, blank samples were inserted every 10 runs. Analyses were performed in the positive and negative ion mode ([Fig. 1](#f1-ol-0-0-11173){ref-type="fig"}).

The method validation was performed based on precision and stability testing, which permitted \<10% relative standard deviation. The results demonstrated the stability of the instrument and the samples ([Tables SI](#SD1-ol-0-0-11173){ref-type="supplementary-material"}--[SIV](#SD1-ol-0-0-11173){ref-type="supplementary-material"}).

### Multivariate statistical analysis

In the present study, multivariate statistical analysis and pattern recognition methods, principal component analysis (PCA) and OPLS-DA, were used to analyze the metabolomics data. PCA resulted in poor distinction between patients and healthy subjects ([Fig. S1](#SD1-ol-0-0-11173){ref-type="supplementary-material"}). The OPLS-DA model was subsequently applied to the metabolomics data to eliminate interference from various non-experimental factors, including sex and age. The model exhibited a trend for distinguishing between patients with GCA and controls ([Fig. 2A and B](#f2-ol-0-0-11173){ref-type="fig"}). The model parameters of R2Y(cum) and Q2 (cum) were 89.6 and 62.1% in the negative pattern and 73.1 and 55.4% in positive pattern, respectively, which indicated that the model had a good fit and predictive ability.

### Identification of potential biomarkers

A total of 27 differential metabolites based on VIP \>1 with S-plot ([Fig. 2C and D](#f2-ol-0-0-11173){ref-type="fig"}) and P\<0.05 ([Table II](#tII-ol-0-0-11173){ref-type="table"}), including L-acetylcarnitine, arachidonic acid, phosphorylcholine and glycocholic acid, were identified and used to establish the OPLS-DA model ([Fig. 2E](#f2-ol-0-0-11173){ref-type="fig"}). This model was able to clearly distinguish patients with GCA from healthy subjects (99.7 and 99.2% for R2Y and Q2, respectively), and compared with [Fig. 2A and B](#f2-ol-0-0-11173){ref-type="fig"}, the clustering effect was improved. Following the 200 iterations of the permutation test, the results revealed that the OPLS-DA model did not result in overfitting as the left replacement R2 and Q2 values were lower than the original point on the right, and the Q2 intercept was \<0 ([Fig. 2F](#f2-ol-0-0-11173){ref-type="fig"}). Therefore, the identified 27 differential metabolites may serve as potential biomarkers for the diagnosis of GCA.

Cluster analysis revealed that the 27 potential biomarkers could be divided into four categories: i) Phospholipids (including phosphorylcholine); ii) cholic acid (including glycocholic acid); iii) unsaturated fatty acids (including arachidonic acid); and iv) amino acids (including L-acetylcarnitine; [Fig. 3A](#f3-ol-0-0-11173){ref-type="fig"}). ROC curve analysis was performed for the candidate biomarkers, and the area under the curve (AUC), sensitivity and specificity were determined ([Tables III](#tIII-ol-0-0-11173){ref-type="table"} and [SV](#SD1-ol-0-0-11173){ref-type="supplementary-material"}). Phosphorylcholine, glycocholic acid, arachidonic acid and L-acetylcarnitine had the largest AUC values (0.913, 0.808, 0.887 and 0.803, respectively), and were thus selected for binary logistic regression to establish a joint index and plot ROC curves ([Fig. 3F](#f3-ol-0-0-11173){ref-type="fig"}). The AUC value of this four biomarker model was 0.990 for the discrimination between patients with GCA and healthy subjects. In addition, the sensitivity and specificity of the model for GCA diagnosis were 97.7 and 95.2%, respectively. Compared with single biomarker models using phosphorylcholine, glycocholic acid, arachidonic acid and L-acetylcarnitine individually, a model comprising the aforementioned four metabolites exhibited improved AUC values, sensitivity and specificity ([Fig. 3B-F](#f3-ol-0-0-11173){ref-type="fig"}).

### Metabolic pathway analysis

To gain a deeper understanding of the biological significance of the potential biomarkers identified in the present study, MetaboAnalyst software (version 4.0) was used for metabolic pathway analysis. The results demonstrated that 'glycerophospholipid metabolism', 'linoleic acid metabolism', 'primary bile acid biosynthesis', 'fatty acid synthesis', 'arachidonic acid metabolism', 'seleno amino acid metabolism' and 'aminoacyl-tRNA biosynthesis' pathways were closely associated with GCA ([Figs. 4](#f4-ol-0-0-11173){ref-type="fig"} and [5](#f5-ol-0-0-11173){ref-type="fig"}). These pathways are mainly associated with energy metabolism, inflammatory reactions and immune responses.

Discussion
==========

The lack of an effective diagnostic model is the major cause contributing to the high mortality of GCA ([@b38-ol-0-0-11173]). To date, a limited number of biomarkers for GCA diagnosis have been identified ([@b23-ol-0-0-11173],[@b25-ol-0-0-11173],[@b39-ol-0-0-11173]). The present study identified 27 biomarkers and established a combined diagnostic model comprising phosphorylcholine, glycocholic acid, arachidonic acid and L-acetylcarnitine for the early diagnosis of GCA. Metabolic pathway enrichment analysis was performed based on all 27 biomarkers identified in the present study. The results revealed that disruptions in glycerophospholipid and linoleic acid metabolism and fatty acid and primary bile acid biosynthesis were significantly associated with the development of GCA. These metabolic disturbances may help understand the underlying pathogenesis of the disease.

The present study used UPLC-Q/TOF MS plasma metabolomics analysis to determine the characteristic metabolic fingerprints in the plasma of patients with GCA. An OPLS-DA model based on plasma metabolomics data exhibited sufficient sensitivity and specificity to distinguish between patients with GCA and healthy controls. Using the cut-off criteria of VIP \>1 and P\<0.05, 27 potential biomarkers for the diagnosis of GCA were identified. Systematic cluster analysis and area under ROC curve values were used to establish a combined diagnostic model consisting of phosphorylcholine, glycocholic acid, arachidonic acid and L-acetylcarnitine for the early diagnosis of GCA. Compared with a single indicator diagnostic model, the combined diagnostic model exhibited significantly improved sensitivity and specificity for the diagnosis of GCA. Additionally, the four key biomarkers and associated metabolic pathways were investigated to shed new light on the pathogenesis of GCA.

L-acetylcarnitine serves as an acetyl carrier and provides an acetyl group for coenzyme A (CoA) ([@b40-ol-0-0-11173]). Acetyl-CoA is required for the *de novo* synthesis of fatty acids ([@b41-ol-0-0-11173]). Hexadecanol-CoA, a product of fatty acid metabolism, is metabolized to produce phosphorylcholine and glycerophospholipid. Acetaldehyde, which is produced from phosphorylcholine, is the link between the glycerophospholipid and pyruvate metabolic pathways ([@b42-ol-0-0-11173]). Additionally, acetyl-CoA synthesis is catalyzed by pyruvate dehydrogenase ([@b43-ol-0-0-11173]). Increased L-acetylcarnitine levels in patients with GCA are associated with excessive fatty acids and previous studies have revealed that fatty acids, particularly unsaturated fatty acids, are a major source of energy for cancer cells ([@b44-ol-0-0-11173],[@b45-ol-0-0-11173]).

Previous studies have demonstrated that phosphorylcholine metabolism is closely associated with the immune response ([@b46-ol-0-0-11173],[@b47-ol-0-0-11173]). Phosphorylcholine is taken up by lymphoid B cells, which produce anti-phosphorylcholine immunoglobulin G and M antibodies that target cancer cells ([@b48-ol-0-0-11173]). However, in the present study, the phosphorylcholine levels in patients with GCA were significantly reduced compared with healthy subjects, suggesting a weakened immune response. Phosphorylcholine synthesizes cytidine 5′-diphosphocholine, a reaction catalyzed by phosphate cytidylyltransferase 1 ([@b49-ol-0-0-11173]). Phosphatidylcholine is subsequently produced by ethanolamine phosphotransferase 1 or choline phosphotransferase 1 ([@b50-ol-0-0-11173]). Phosphatidylcholine promotes apoptosis in the human gastric cancer cell line BGC823, downregulates the expression of ATP binding cassette subfamily F member 2 and reduces the number of cancer stem cells ([@b51-ol-0-0-11173],[@b52-ol-0-0-11173]). Therefore, decreased phosphorylcholine levels in patients with GCA may provide a favorable environment for the proliferation of GCA cells.

Phosphatidylcholine is used to synthesize linoleic acid through the linoleic acid metabolic pathway, which can be further used in the synthesis of arachidonic acid ([@b53-ol-0-0-11173]). The present study revealed that the levels of arachidonic acid in patients with GCA were significantly increased compared with healthy subjects. Eicosanoids, including prostaglandins (PGs) and leukotrienes (LTs) are synthesized by cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) from arachidonic acid ([@b54-ol-0-0-11173]). In turn, PGs and LTs upregulate the expression of COX-2 and 5-LOX via a positive feedback amplification mechanism ([@b55-ol-0-0-11173],[@b56-ol-0-0-11173]). PGs and LTs promote cancer cell proliferation and tumor growth by activating the mitogen-activated protein kinase/nuclear factor-κB signaling pathway ([@b57-ol-0-0-11173],[@b58-ol-0-0-11173]). In addition, PGs and LTs increase the survival, proliferation, invasion and migration and decrease apoptosis of tumor epithelial cells by regulating multiple signaling pathways ([@b56-ol-0-0-11173]), such as protein kinase C/extracellular signal regulated kinase pathway and Ras-Raf-Erk pathway ([@b59-ol-0-0-11173],[@b60-ol-0-0-11173]). Therefore, the arachidonic acid content in patients with GCA may increase to allow the proliferation of tumor cells.

Bile acids, particularly unconjugated bile acids, are implicated in gastroduodenal reflux ([@b61-ol-0-0-11173]). Long-term gastroduodenal reflux may result in chronic inflammation ([@b62-ol-0-0-11173]), which may lead to muscle atrophy in the stomach tissue, intestinal erosion and the development of cancer ([@b63-ol-0-0-11173]). The accumulation of bile salts can contribute towards progressive liver damage and fibrosis; therefore, the levels of bile acids in the blood and tissues are highly regulated ([@b64-ol-0-0-11173]). Glycocholic acid, which is a combination of acetyl glycine (produced by cytidine 5′-diphosphocholine) and bile acid, serves as a detergent and promotes the absorption of fat as well as its own absorption, thereby preventing cholestasis ([@b65-ol-0-0-11173]). The present study revealed a significant decrease in glycocholic acid levels in patients with GCA compared with healthy subjects, consistent with the aforementioned studies.

A large sample size is often required for clinical research due to individual variations. However, the present study implemented strict inclusion/exclusion criteria and required informed consent for each patient, which resulted in only 21 patients being available for sampling. One limitation of this study is the low number of samples, which does not allow further analysis, for example, to identify the biomarkers for TNM staging of GCA, which would require a large number of additional clinical samples. Future studies will continue to collect clinical samples and perform in-depth analysis. Additionally, digestive tract diseases are closely associated with imbalances in the intestinal flora ([@b66-ol-0-0-11173]). As a limited number of studies have investigated the association between GCA and the intestinal flora, future studies are warranted. The multi-omics fusion of metabolomics, proteomics, genomics and metagenomics may aid the optimization of the early diagnostic model of GCA described in the current study and elucidate the underlying mechanisms of the disease. The present study identified four biomarkers and established a combined diagnostic model for early diagnosis of GCA, which may achieve progress in the prevention and treatment of GCA. Further metabolic pathway analysis is required to better understand the molecular pathogenesis of GCA.
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![Multivariate statistical analysis for GCA (blue circles) and healthy controls (red triangles). (A) OPLS-DA score plot with all variables Pareto scaled using the metabolomics data in the positive ion modes. (B) S-plot of all compounds that were detected in the positive ion modes. (C) OPLS-DA score plot with all variables Pareto scaled using the metabolomics data in the negative ion modes. (D) S-plot of all compounds that were detected in the negative ion modes. (E) OPLS-DA score plot based on 27 differential metabolites of GCA. (F) Permutation test following 200 iterations. The vertical axis corresponds to R2 and Q2 values of each model. R2 was the estimate of 'goodness of fit' of the model, and Q2 is the estimate of the ability of prediction. The horizontal axis corresponds to the correlation coefficient between the original Y and the permuted Y. GCA, gastric cardia adenocarcinoma; OPLS-DA, orthogonal partial least squares discrimination analysis.](ol-19-01-0681-g01){#f2-ol-0-0-11173}

![Results of cluster and ROC curve analysis. (A) Results of cluster analysis of 27 potential biomarkers. ROC of (B) L-acetylcarnitine, (C) phosphorylcholine, (D) glycocholic acid and (E) arachidonic acid. (F) ROC of the combined model (1, phosphorylcholine; 2, L-acetylcarnitine; 3, arachidonic acid; 4, glycocholic acid). ROC, receiver operating characteristic.](ol-19-01-0681-g02){#f3-ol-0-0-11173}
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###### 

Clinical information of the enrolled subjects.

  Characteristics                                           Healthy      GCA
  --------------------------------------------------------- ------------ ------------
  Sex (male/female)                                         14/34        14/7
  Age, years                                                52.15±6.96   66.00±8.48
  TNM^[a](#tfn1-ol-0-0-11173){ref-type="table-fn"}^ stage                
  IA                                                        --           2
  IB                                                        --           1
  IIA                                                       --           1
  IIIA                                                      --           7
  IIIC                                                      --           9
  IV                                                        --           1

The Tumor-Node-Metastasis Classification of Malignant Tumors (TNM) is a globally recognized standard for classifying the extent of spread of cancer. It is a classification system of the anatomical extent of tumor cancers. T describes the size of the original (primary) tumor and whether it has invaded nearby tissue, N describes nearby (regional) lymph nodes that are involved, M describes distant metastasis (spread of cancer from one part of the body to another) ([@b67-ol-0-0-11173]). GCA, gastric cardia adenocarcinoma.

###### 

Potential biomarkers identified using variable importance in the projection \>1 and P\<0.05 as cut-off values.

                                                                                             Relative content                     
  ---- -------- ---------- ----------------------------- -------------- -------------------- ------------------ ----------------- ------
  1    0.705    204.1238   L-Acetylcarnitine             HMDB00201      C~9~H~17~NO~4~       10772.0±3213.5     17417.0±9987.9    Up
  2    2.311    203.0824   L-Tryptophan                  HMDB00929      C~11~H~12~N~2~O~2~   10400.0±1889.4     7700.6±2411.7     Up
  3    2.805    165.0553   Phosphorylcholine             HMDB01565      C~5~H~15~NO~4~P^+^   2323.9±1578.1      62.7±107.2        Down
  4    2.908    239.0917   N-Acetyl-L-aspartic acid      HMDB00812      C~6~H~9~NO~5~        1883.9±1057.6      774.6±639.0       Down
  5    3.804    464.3020   Glycocholic acid              HMDB00138      C~26~H~43~NO~6~      1875.3±2860.8      243.2±430.6       Down
  6    3.959    316.2488   Decanoylcarnitine             HMDB00651      C~17~H~33~NO~4~      3228.3±2037.3      1535.4±1076.9     Down
  7    4.309    448.3076   Glycoursodeoxycholic acid     HMDB00708      C~26~H~43~NO~5~      6251.0±7940.5      1462.8±1572.0     Down
  8    5.575    502.2943   LysoPE (18:0/0:0)             HMDB11130      C~23~H~48~NO~7~P     2441.3±1604.9      1232.6±1170.7     Down
  9    5.647    512.2998   LysoPC (14:0)                 HMDB10379      C~22~H~46~NO~7~P     2085.0±1076.3      927.0±695.2       Down
  10   5.863    494.3253   LysoPC (16:1(9Z))             HMDB10383      C~24~H~48~NO~7~P     7636.3±3484.4      4788.1±3245.4     Down
  11   6.059    476.2783   LysoPE \[18:2(9Z,12Z)/0:0\]   HMDB11507      C~23~H~44~NO~7~P     1907.3±584.3       1107.1±615.8      Down
  12   6.306    530.3256   LysoPE (0:0/20:0)             HMDB11481      C~25~H~52~NO~7~P     1435.2±734.00      615.1±489.4       Down
  13   6.636    522.3590   LysoPC (18:1(9Z))             HMDB02815      C~26~H~52~NO~7~P     17304.0±3917.6     13519.0±5793.0    Down
  14   6.749    452.2790   LysoPE (16:0/0:0)             HMDB11503      C~21~H~44~NO~7~P     9912.0±3133.2      7441.4±2151.0     Down
  15   6.749    454.2938   PC (13:0/0:0)                 LMGP01050001   C~21~H~44~NO~7~P     5164.7±1852.0      3637.4±1291.2     Down
  16   6.831    506.3347   Glucosylsphingosine           HMDB00596      C~24~H~47~NO~7~      87740.0±24187.0    65800.0±32818.0   Down
  17   7.377    508.3429   LysoPE (20:0/0:0)             HMDB11511      C~25~H~52~NO~7~P     15944.0±3227.1     11173.0±3174.6    Down
  18   7.479    279.2357   Linoleic acid                 HMDB00673      C~18~H~32~O~2~       30629.0±12293.0    48714.0±20640     Up
  19   7.48     325.2127   Eicosapentaenoic acid         HMDB01999      C~20~H~30~O~2~       6963.6±1390.8      9555.2±1956.8     Up
  20   7.635    482.3253   LysoPC (15:0)                 HMDB10381      C~23~H~48~NO~7~P     8755.0±2666.9      6452.4±2019.7     Down
  21   7.963    255.2328   Palmitic acid                 HMDB00220      C~16~H~32~O~2~       9627.4±2268.2      11912.0±2825.9    Up
  22   8.057    305.2453   Oleic acid                    HMDB00207      C~18~H~34~O~2~       3682.3±1394.0      6233.2±2806.1     Up
  23   8.067    349.2362   Arachidonic acid              HMDB01043      C~20~H~32~O~2~       10783.0±1696.6     13668.0±1853.6    Up
  24   9.538    774.5313   PC \[14:1(9Z)/18:1(9Z)\]      HMDB07906      C~40~H~76~NO~8~P     4350.9±1504.6      2188.9±1750.0     Down
  25   10.424   834.6118   Cholic acid                   HMDB00619      C~24~H~40~O~5~       115535.0±41829.0   77787.0±26499.0   Down
  26   13.534   182.9840   Selenohomocysteine            HMDB04119      C~4~H~8~NO~2~Se      16307.0±1652.6     17852.0±2159.8    Up
  27   14.811   118.0863   L-valine                      HMDB00883      C~5~H~11~NO~2~       17456.0±2332.0     19214.0±2771.1    Up

GCA, gastric cardia adenocarcinoma; PC, phosphatidylcholine; LysoPC, lysophosphatidylcholine; LysoPE, lysophosphatidylethanolamine.

###### 

Receiver operating characteristic curve analysis of the four biomarkers (phosphorylcholine, L-acetylcarnitine, arachidonic acid and glycocholic acid) and the combined model.

                                                                                         95% CI                   
  ---------------------------------------------------------------------- ------- ------- -------- ------- ------- -------
  Phosphorylcholine                                                      0.913   0.035   0.843    0.982   0.854   1.000
  L-Acetylcarnitine                                                      0.803   0.054   0.698    0.907   0.762   0.708
  Arachidonic acid                                                       0.887   0.050   0.789    0.985   0.905   0.833
  Glycocholic acid                                                       0.808   0.056   0.697    0.918   0.729   0.810
  Four metabolites model^[a](#tfn3-ol-0-0-11173){ref-type="table-fn"}^   0.990   0.008   0.000    1.000   0.979   0.952

The four metabolites model comprised phosphorylcholine, L-acetylcarnitine, arachidonic acid and glycocholic acid. CI, confidence interval; AUC, area under the curve.

[^1]: Contributed equally
